XML 39 R25.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2024
Income Tax Disclosure [Abstract] |
Income Taxes | Note 15. Income Taxes U.S and foreign components of consolidated loss before income taxes for the years ended December 31, 2024, 2023 and 2022, was as follows (in thousands):
|  | 2024 |  |  | 2023 |  |  | 2022 |
Loss before income taxes: |  |  |  |  |  |  |  |  |
U.S. |  | $ | (21,318 | ) |  | $ | (38,281 | ) |  | $ | (43,096 | )
Foreign |  |  | 562 |  |  |  | 959 |  |  |  | 759 |
Loss before income taxes |  | $ | (20,756 | ) |  | $ | (37,322 | ) |  | $ | (42,337 | )
The provision for income taxes for the years ended December 31, 2024, 2023 and 2022, was as follows (in thousands):
|  | 2024 |  |  | 2023 |  |  | 2022 |
Provision for income taxes: |  |  |  |  |  |  |  |  |
Current: |  |  |  |  |  |  |  |  |
Foreign |  | $ | 130 |  |  | $ | 285 |  |  | $ | 520 |
Federal |  |  | — |  |  |  | — |  |  |  | — |
State |  |  | 70 |  |  |  | 36 |  |  |  | 5 |
Total current |  |  | 200 |  |  |  | 321 |  |  |  | 525 |
Deferred: |  |  |  |  |  |  |  |  |
Foreign |  |  | — |  |  |  | — |  |  |  | — |
Federal |  |  | 3 |  |  |  | 2 |  |  |  | (18 | )
State |  |  | 2 |  |  |  | 2 |  |  |  | (19 | )
Total deferred |  |  | 5 |  |  |  | 4 |  |  |  | (37 | )
Provision for income taxes |  | $ | 205 |  |  | $ | 325 |  |  | $ | 488 |
The difference between the provision for income taxes and the amount computed by applying the federal statutory income tax rate to loss before taxes for the years ended December 31, 2024, 2023 and 2022, was as follows (in thousands):
|  | 2024 |  |  | 2023 |  |  | 2022 |
Federal statutory tax |  | $ | (4,359 | ) |  | $ | (7,838 | ) |  | $ | (8,891 | )
Federal research credits |  |  | (853 | ) |  |  | (1,065 | ) |  |  | (1,874 | )
State research credits |  |  | (767 | ) |  |  | (642 | ) |  |  | (822 | )
Expiration of federal carryovers |  |  | 5,206 |  |  |  | 7,284 |  |  |  | 4,858 |
Change in valuation allowance |  |  | (2,357 | ) |  |  | 1,361 |  |  |  | 6,379 |
Compensation related items |  |  | 4,015 |  |  |  | 3,257 |  |  |  | 1,794 |
State taxes |  |  | (259 | ) |  |  | (1,710 | ) |  |  | (1,127 | )
Revision to prior year items |  |  | (676 | ) |  |  | (664 | ) |  |  | — |
Other |  |  | 255 |  |  |  | 342 |  |  |  | 171 |
Provision for income taxes |  | $ | 205 |  |  | $ | 325 |  |  | $ | 488 |
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes at the enacted rates. The significant components of the Company’s deferred tax assets and liabilities at December 31, 2024, 2023 and 2022, were as follows (in thousands):
|  | December 31, |
|  | 2024 |  |  | 2023 |
Deferred tax assets: |  |  |  |  |  |
Net operating loss carryforwards |  | $ | 127,184 |  |  | $ | 133,476 |
Research and development credit carryforwards |  |  | 29,739 |  |  |  | 28,567 |
Capitalized research and development |  |  | 35,861 |  |  |  | 33,571 |
Compensation related items |  |  | 9,437 |  |  |  | 10,306 |
Operating leases |  |  | 3,005 |  |  |  | 3,462 |
Other |  |  | 10,928 |  |  |  | 9,823 |
Total deferred tax assets |  |  | 216,154 |  |  |  | 219,205 |
Valuation allowance |  |  | (214,321 | ) |  |  | (216,888 | )
Net deferred tax assets |  | $ | 1,833 |  |  | $ | 2,317 |
Deferred tax liabilities: |  |  |  |  |  |
Right-of-use assets |  | $ | 1,676 |  |  | $ | 2,173 |
Other |  |  | 226 |  |  |  | 209 |
Total deferred tax liabilities |  | $ | 1,902 |  |  | $ | 2,382 |
The valuation allowance decreased by $2.6 million for the year ended December 31, 2024, compared to the increase of $1.0 million and $6.4 million for the years ended December 31, 2023 and 2022, respectively. The Company believes that, based on a number of factors, the available objective evidence creates sufficient uncertainty regarding the realizability of the deferred tax assets such that a valuation allowance has been recorded. These factors include the Company’s history of net losses since its inception, the need for regulatory approval of the Company’s products prior to commercialization and expected near-term future losses. The Company expects to maintain a valuation allowance until circumstances change. For the year ended December 31, 2024, the Company reported pretax net losses on its consolidated statement of operations and calculated taxable losses for federal purposes and varying taxable income and losses for state purposes based on individual jurisdictions. The differences between reported net loss and taxable income or loss are due to differences between book accounting and the respective tax laws. The most notable differences are the treatment of research and development expenses and compensation related items The Company’s tax losses and credits are subject to varying carryforward periods. The gross amounts and dates of expiration of the significant carryforwards are as follows:
|  |  |  |  | Expires |  |  | Expires |  |  | Expires |  |  | No |
|  | Total |  |  | 2025-2027 |  |  | 2028-2034 |  |  | 2035-2044 |  |  | Expiration |
Federal losses carryovers |  | $ | 559,551 |  |  | $ | 58,345 |  |  | $ | 193,684 |  |  | $ | 116,604 |  |  | $ | 190,918 |
California loss carryovers |  |  | 108,685 |  |  |  | — |  |  |  | 67,796 |  |  |  | 40,889 |  |  |  | — |
Other state loss carryovers |  |  | 45,090 |  |  |  | 128 |  |  |  | 2,762 |  |  |  | 30,630 |  |  |  | 11,570 |
Federal research credits |  |  | 17,074 |  |  |  | 1,279 |  |  |  | 1,927 |  |  |  | 13,868 |  |  |  | — |
California research credits |  |  | 16,011 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 16,011 |
Federal foreign tax credits |  |  | 610 |  |  |  | 610 |  |  |  | — |  |  |  | — |  |  |  | — |
The Company’s ability to utilize net operating loss and research and development credit carryforwards is limited by (a) its ability to generate future taxable income, (b) varying apportionment and allocation rules, and (c) limitations pursuant to the ownership change rules in accordance with Section 382 of the Internal Revenue Code of 1986 and with Section 383 of the Internal Revenue Code of 1986, as well as similar state provisions. The Company’s unrecognized tax benefits primarily relate to federal and California research tax credits. These tax credits have not been utilized on any tax return and currently have no impact on the Company’s tax expense due to the Company’s operating losses and the related valuation allowances. There are additional unrecognized tax benefits related to foreign activities. The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands):
|  | December 31, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Unrecognized tax benefits at beginning of period |  | $ | 7,924 |  |  | $ | 8,652 |
Decreases related to expired carryforwards |  |  | (344 | ) |  |  | (1,126 | )
Decreases related to administrative proceedings |  |  | (127 | ) |  |  | — |
Increases related to prior year tax positions |  |  | 94 |  |  |  | 100 |
Increases related to current year tax positions |  |  | 290 |  |  |  | 298 |
Unrecognized tax benefits at end of period |  | $ | 7,837 |  |  | $ | 7,924 |
The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration